Skip to main content

A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma

Status: complete

The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer

Inclusion Criteria

Advanced Renal Cell Carcinoma
Must have at least 1 lesion with measurable disease
Life expectancy of at least 3 months
Karnofsky Performance Status (KPS) must be =>70%

Exclusion Criteria

Patients/subjects with suspected or known central nervous system metastases unless adequately treated
Patients/subjects with autoimmune disease
Patients/subjects who need daily oxygen therapy Other protocol defined inclusion/exclusion criteria apply

Have a question?
We're here to help

Chat with us: LiveHelp
Call us: 1-800-4-CANCER
(1-800-422-6237)

Which trials are right for you?

Use the checklist in our guide to gather the information you’ll need.